DE69423773D1 - Behandlungsverfahren unter verwendung unilamellar-liposomaler arachiddonsäuremetabolit-formulierungen - Google Patents

Behandlungsverfahren unter verwendung unilamellar-liposomaler arachiddonsäuremetabolit-formulierungen

Info

Publication number
DE69423773D1
DE69423773D1 DE69423773T DE69423773T DE69423773D1 DE 69423773 D1 DE69423773 D1 DE 69423773D1 DE 69423773 T DE69423773 T DE 69423773T DE 69423773 T DE69423773 T DE 69423773T DE 69423773 D1 DE69423773 D1 DE 69423773D1
Authority
DE
Germany
Prior art keywords
liposomal
arachiddonic
unilamellar
acid metabolite
treatment method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69423773T
Other languages
English (en)
Other versions
DE69423773T2 (de
Inventor
Marc J Ostro
Andrew S Janoff
Sharma R Minchey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Application granted granted Critical
Publication of DE69423773D1 publication Critical patent/DE69423773D1/de
Publication of DE69423773T2 publication Critical patent/DE69423773T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
DE69423773T 1993-11-04 1994-11-03 Behandlungsverfahren unter verwendung unilamellar-liposomaler arachiddonsäuremetabolit-formulierungen Expired - Fee Related DE69423773T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14789893A 1993-11-04 1993-11-04
US15285293A 1993-11-16 1993-11-16
US18008994A 1994-01-11 1994-01-11
PCT/US1994/012579 WO1995012388A1 (en) 1993-11-04 1994-11-03 Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations

Publications (2)

Publication Number Publication Date
DE69423773D1 true DE69423773D1 (de) 2000-05-04
DE69423773T2 DE69423773T2 (de) 2000-07-20

Family

ID=27386612

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69423773T Expired - Fee Related DE69423773T2 (de) 1993-11-04 1994-11-03 Behandlungsverfahren unter verwendung unilamellar-liposomaler arachiddonsäuremetabolit-formulierungen
DE69420859T Expired - Fee Related DE69420859T2 (de) 1993-11-04 1994-11-03 Multilamellare liposomformulierungen, die einen arachidsäuremetaboliten enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69420859T Expired - Fee Related DE69420859T2 (de) 1993-11-04 1994-11-03 Multilamellare liposomformulierungen, die einen arachidsäuremetaboliten enthalten

Country Status (13)

Country Link
EP (2) EP0726764B1 (de)
JP (2) JPH09511216A (de)
KR (2) KR100355246B1 (de)
AT (2) ATE191141T1 (de)
AU (2) AU687921B2 (de)
CA (2) CA2175896A1 (de)
DE (2) DE69423773T2 (de)
DK (2) DK0726763T3 (de)
ES (2) ES2136271T3 (de)
GR (2) GR3032006T3 (de)
NO (2) NO312810B1 (de)
PT (1) PT726763E (de)
WO (2) WO1995012389A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
ATE233552T1 (de) * 1996-07-22 2003-03-15 Monsanto Co Thiol-sulfonen als metalloproteinaseinhibitoren
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
WO1999025687A1 (en) 1997-11-14 1999-05-27 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
KR20010102000A (ko) 1999-02-08 2001-11-15 윌리암스 로저 에이 술파마토 히드록삼산 메탈로프로테아제 억제제
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
WO2013039851A1 (en) 2011-09-12 2013-03-21 Mallinckrodt Llc Optical agents for imaging and visualization of matrix metalloproteinase enzymes
CN111053743B (zh) * 2018-10-16 2023-07-14 石药集团中奇制药技术（石家庄）有限公司 一种前列地尔脂质体及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
WO1988009170A1 (en) * 1987-05-22 1988-12-01 The Liposome Company, Inc. Prostaglandin-lipid formulations
JPH0395118A (ja) * 1989-09-07 1991-04-19 Green Cross Corp:The プロスタグランジン含有脂肪小体製剤
JPH04356421A (ja) * 1991-03-06 1992-12-10 Green Cross Corp:The プロスタグランジン類含有脂肪小体組成物
ES2128343T3 (es) * 1991-05-07 1999-05-16 Liposome Co Inc Formulaciones de prostaglandina liposomica.
JPH05139977A (ja) * 1991-05-17 1993-06-08 Green Cross Corp:The プロスタグランジン類リポソーム複合体を充填した注射器

Also Published As

Publication number Publication date
AU687921B2 (en) 1998-03-05
GR3033817T3 (en) 2000-10-31
DE69423773T2 (de) 2000-07-20
WO1995012389A1 (en) 1995-05-11
WO1995012388A1 (en) 1995-05-11
JPH09504793A (ja) 1997-05-13
KR960705544A (ko) 1996-11-08
KR100355246B1 (ko) 2003-01-06
AU8130894A (en) 1995-05-23
KR960705543A (ko) 1996-11-08
EP0726764A1 (de) 1996-08-21
DK0726764T3 (da) 1999-12-20
ATE184785T1 (de) 1999-10-15
ES2136271T3 (es) 1999-11-16
KR100355247B1 (ko) 2003-01-24
NO961778D0 (no) 1996-05-02
CA2175057A1 (en) 1995-05-11
NO312809B1 (no) 2002-07-08
EP0726763B1 (de) 2000-03-29
NO961779L (no) 1996-05-02
NO312810B1 (no) 2002-07-08
DE69420859D1 (de) 1999-10-28
GR3032006T3 (en) 2000-03-31
PT726763E (pt) 2000-09-29
AU8132694A (en) 1995-05-23
DK0726763T3 (da) 2000-07-10
ATE191141T1 (de) 2000-04-15
CA2175896A1 (en) 1995-05-11
EP0726763A1 (de) 1996-08-21
DE69420859T2 (de) 2000-01-05
NO961779D0 (no) 1996-05-02
JPH09511216A (ja) 1997-11-11
ES2144118T3 (es) 2000-06-01
NO961778L (no) 1996-06-25
EP0726764B1 (de) 1999-09-22

Similar Documents

Publication Publication Date Title
DE69423773D1 (de) Behandlungsverfahren unter verwendung unilamellar-liposomaler arachiddonsäuremetabolit-formulierungen
ES2180635T3 (es) Metodo para reducir la grasa corporal en animales mediante la administracion de acido linoleico conjugado.
NO20030374L (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
DK0800503T3 (da) Hidtil ukendte trien-retinoidforbindelser og fremgangsmåder
ES2164434T3 (es) Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8.
AR021946A1 (es) Composiciones que contienen feniramina y metodo para el tratamiento de las respuestas alergicas
ES2180164T3 (es) Agentes acuosos para el cuidado de la piel y del cabello.
ATE135560T1 (de) Topisches behandlungsmittel enthaltend lipidvesikeln die mindestens ein mineralwasser einkapseln
ES2192669T3 (es) Uso de proteinas como agentes frente a enfermedades autoinmunes.
DE69416425D1 (de) Arachidonsäuremetaboliten enthaltende interdigitations-fusions-liposomen
NO20023111D0 (no) Utvortes preparat for behandling av pruritus
AR019893A1 (es) Un metodo para reducir o evitar el mal olor
DE69722178D1 (de) Therapeutischer wirkstoff für augenerkrankungen
FI910308A0 (fi) Vattenloesliga vitamin a preparationer foer applicering pao huden.
ECSP951497A (es) Proteina mayor de leishmanias acido nucleico codante para esta proteina y sus aplicaciones
CO4850559A1 (es) Metodo de reduccion o prevencion del mal olor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee